On the other hand, inhibition of YAP/TAZ increases cytotoxicity of chemotherapy and sensitivity to various target therapies including EGFR-TKIs and MEK inhibitors in NSCLC [26,27]. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.